Cargando…
Microfluidics for COVID-19: From Current Work to Future Perspective
Spread of coronavirus disease 2019 (COVID-19) has significantly impacted the public health and economic sectors. It is urgently necessary to develop rapid, convenient, and cost-effective point-of-care testing (POCT) technologies for the early diagnosis and control of the plague’s transmission. Devel...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953302/ https://www.ncbi.nlm.nih.gov/pubmed/36831930 http://dx.doi.org/10.3390/bios13020163 |
_version_ | 1784893844686372864 |
---|---|
author | Li, Qi Zhou, Xingchen Wang, Qian Liu, Wenfang Chen, Chuanpin |
author_facet | Li, Qi Zhou, Xingchen Wang, Qian Liu, Wenfang Chen, Chuanpin |
author_sort | Li, Qi |
collection | PubMed |
description | Spread of coronavirus disease 2019 (COVID-19) has significantly impacted the public health and economic sectors. It is urgently necessary to develop rapid, convenient, and cost-effective point-of-care testing (POCT) technologies for the early diagnosis and control of the plague’s transmission. Developing POCT methods and related devices is critical for achieving point-of-care diagnosis. With the advantages of miniaturization, high throughput, small sample requirements, and low actual consumption, microfluidics is an essential technology for the development of POCT devices. In this review, according to the different driving forces of the fluid, we introduce the common POCT devices based on microfluidic technology on the market, including paper-based microfluidic, centrifugal microfluidic, optical fluid, and digital microfluidic platforms. Furthermore, various microfluidic-based assays for diagnosing COVID-19 are summarized, including immunoassays, such as ELISA, and molecular assays, such as PCR. Finally, the challenges of and future perspectives on microfluidic device design and development are presented. The ultimate goals of this paper are to provide new insights and directions for the development of microfluidic diagnostics while expecting to contribute to the control of COVID-19. |
format | Online Article Text |
id | pubmed-9953302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99533022023-02-25 Microfluidics for COVID-19: From Current Work to Future Perspective Li, Qi Zhou, Xingchen Wang, Qian Liu, Wenfang Chen, Chuanpin Biosensors (Basel) Review Spread of coronavirus disease 2019 (COVID-19) has significantly impacted the public health and economic sectors. It is urgently necessary to develop rapid, convenient, and cost-effective point-of-care testing (POCT) technologies for the early diagnosis and control of the plague’s transmission. Developing POCT methods and related devices is critical for achieving point-of-care diagnosis. With the advantages of miniaturization, high throughput, small sample requirements, and low actual consumption, microfluidics is an essential technology for the development of POCT devices. In this review, according to the different driving forces of the fluid, we introduce the common POCT devices based on microfluidic technology on the market, including paper-based microfluidic, centrifugal microfluidic, optical fluid, and digital microfluidic platforms. Furthermore, various microfluidic-based assays for diagnosing COVID-19 are summarized, including immunoassays, such as ELISA, and molecular assays, such as PCR. Finally, the challenges of and future perspectives on microfluidic device design and development are presented. The ultimate goals of this paper are to provide new insights and directions for the development of microfluidic diagnostics while expecting to contribute to the control of COVID-19. MDPI 2023-01-20 /pmc/articles/PMC9953302/ /pubmed/36831930 http://dx.doi.org/10.3390/bios13020163 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Qi Zhou, Xingchen Wang, Qian Liu, Wenfang Chen, Chuanpin Microfluidics for COVID-19: From Current Work to Future Perspective |
title | Microfluidics for COVID-19: From Current Work to Future Perspective |
title_full | Microfluidics for COVID-19: From Current Work to Future Perspective |
title_fullStr | Microfluidics for COVID-19: From Current Work to Future Perspective |
title_full_unstemmed | Microfluidics for COVID-19: From Current Work to Future Perspective |
title_short | Microfluidics for COVID-19: From Current Work to Future Perspective |
title_sort | microfluidics for covid-19: from current work to future perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953302/ https://www.ncbi.nlm.nih.gov/pubmed/36831930 http://dx.doi.org/10.3390/bios13020163 |
work_keys_str_mv | AT liqi microfluidicsforcovid19fromcurrentworktofutureperspective AT zhouxingchen microfluidicsforcovid19fromcurrentworktofutureperspective AT wangqian microfluidicsforcovid19fromcurrentworktofutureperspective AT liuwenfang microfluidicsforcovid19fromcurrentworktofutureperspective AT chenchuanpin microfluidicsforcovid19fromcurrentworktofutureperspective |